Home » Newsletters » BioWorld

BioWorld

Oct. 1, 1992

View Archived Issues

GLYCOMED COMPLETES SAFETY TRIALS OF EYE DRUG

RIGHTS TO PROTEASE INHIBITOR ASSIGNED TO INCYTE

RESEARCHERS SHARE UNPUBLISHED GENOME DATA

FDA APPROVES IN-OFFICE TEST

HYBRIDON ALLOWED PATENT APPLICATION

DNX GETS RIGHTS TO BLOOD SUBSTITUTE TECHNOLOGIES

GENPHARM IN DEAL WITH LILLY

INDUSTRY CEOS TAKE ON ISSUES

BIOSURFACE OBTAINS PATENT

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...